4.98
Precedente Chiudi:
$4.91
Aprire:
$4.86
Volume 24 ore:
186.33K
Relative Volume:
0.67
Capitalizzazione di mercato:
$160.79M
Reddito:
$4.06M
Utile/perdita netta:
$-50.22M
Rapporto P/E:
-3.0769
EPS:
-1.6185
Flusso di cassa netto:
$-25.37M
1 W Prestazione:
+8.73%
1M Prestazione:
+57.10%
6M Prestazione:
-41.27%
1 anno Prestazione:
+0.00%
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics Inc
|
4.98 | 158.53M | 4.06M | -50.22M | -25.37M | -1.6185 |
|
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
|
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
MSN Money - msn.com
Number of shareholders of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
IMDX: Insight Molecular Diagnostics Inc.Comparative Chart - Zacks Investment Research
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
iMDx will post quarterly results May 13, then take investor questions live - Stock Titan
iMDx to Release First Quarter 2026 Results on May 13, 2026 - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Pfizer (PFE) and Travere Therapeutics (TVTX) - The Globe and Mail
Insight Molecular Corrects Bylaws Disclosure in Annual Report - TipRanks
IMDX (NASDAQ: IMDX) outlines 2026 proxy votes, FDA dd-cfDNA strategy - Stock Titan
[8-K] Insight Molecular Diagnostics Inc. Reports Material Event - Stock Titan
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones - Yahoo Finance
Broadwood Partners, Neal C. Bradsher buy $2.03m of Insight Molecular Diagnostics - Investing.com India
Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares - Stock Titan
Broadwood entities add 570K IMDX shares, hold 12.7M plus warrants - Stock Titan
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Major Investor Makes Bold Move Into Insight Molecular Diagnostics - TipRanks
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics By Investing.com - Investing.com South Africa
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics - Investing.com
Broadwood boosts Insight Molecular (IMDX) stake with 182,861-share buy - Stock Titan
Insight (IMDX) Stock Range-Bound (Marginal Loss) 2026-04-20Gap Down Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Stock List: Research Stocks from Around the World - GuruFocus
IMDX: GraftAssure's decentralized PCR test drives transplant diagnostics innovation and market expansion - TradingView
IMDX: GraftAssure aims to transform transplant diagnostics with decentralized, high-margin testing - TradingView — Track All Markets
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Kidney transplant test data heads to 3 global medical meetings - Stock Titan
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay - GlobeNewswire
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance
IMDX Options Volatility — NASDAQ:IMDX - TradingView
IMDX Options Chain — NASDAQ:IMDX - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Capital expenditures of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
IMDX Technical Analysis & Stock Price Forecast - Intellectia AI
Insight Molecular Diagnostics Inc. Stock Forecast Summary - Meyka
IMDX Submits Kitted Transplant Rejection Test for FDA Review - Clinical Lab Products
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):